Imago BioSciences (IMGO) Stock Price, News & Analysis

Company Overview

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $36.01 to $36.01
• 50-Day Range: $35.78 to $36.01
• 52-Week Range: $11.56 to $36.09
• Volume: N/A
• Average Volume: 171,367 shs
• Market Capitalization: $1.22 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IMGO Stock Analysis - Frequently Asked Questions

How were Imago BioSciences' earnings last quarter?

Imago BioSciences, Inc. (NASDAQ:IMGO) issued its earnings results on Wednesday, November, 10th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.10.

When did Imago BioSciences IPO?

Imago BioSciences (IMGO) raised $105 million in an initial public offering on Friday, July 16th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share.

What other stocks do shareholders of Imago BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Imago BioSciences investors own include Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Advanced Micro Devices (AMD) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 7/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:IMGO
• CIK: 1623715
• Web: www.imagobio.com
• Phone: 415-529-5055
• Fax: N/A
• Employees: 27
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$42.31 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -31.85%
• Return on Assets: -30.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.15
• Quick Ratio: 13.16

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.40 per share
• Price / Book: 5.63

Miscellaneous

• Outstanding Shares: 33,822,000
• Free Float: 28,783,000
• Market Cap: $1.22 billion
• Optionable: Not Optionable
• Beta: 2.82